(Q38180344)

30 August 2017

Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy (English)

1 reference

30 August 2017

0 references

1 reference

1 reference

Lei Chang

1

1 reference

30 August 2017

Peter H Graham

2

1 reference

30 August 2017

Jingli Hao

3

1 reference

30 August 2017

Joseph Bucci

4

1 reference

30 August 2017

Paul J Cozzi

5

1 reference

30 August 2017

John H Kearsley

6

1 reference

30 August 2017

Yong Li

7

1 reference

30 August 2017

language of work or name

1 reference

1 September 2014

1 reference

Cancer and Metastasis Reviews

30 August 2017

1 reference

30 August 2017

33

1 reference

30 August 2017

2-3

1 reference

30 August 2017

469-496

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-014-9493-5

30 August 2017

0 references

cites work

New therapies for castration-resistant prostate cancer: efficacy and safety

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Perspectives on mTOR inhibitors for castration-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Prostate cancer stem cells and their potential roles in metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

CD44 is a biomarker associated with human prostate cancer radiation sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

An update on the changing indications for androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Fast neutron irradiation for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The effect of photon energy on intensity-modulated radiation therapy (IMRT) plans for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Image-guided dose-escalated intensity-modulated radiation therapy for prostate cancer: treating to doses beyond 78 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

External-beam radiotherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

What dose of external-beam radiation is high enough for prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The protein kinase B/Akt signalling pathway in human malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The RAS signal transduction pathway and its role in radiation sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Unravelling the activation mechanisms of protein kinase B/Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Targeting prostate cancer based on signal transduction and cell cycle pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Role of autophagy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The role of autophagy in cancer development and response to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

PTEN status in advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Analysis of complex protein kinase B signalling pathways in human prostate cancer samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

TOR signaling is a determinant of cell survival in response to DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Autophagy as a cell death and tumor suppressor mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Crosstalk between Bak/Bax and mTOR signaling regulates radiation-induced autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

A matter of life or death (or both): understanding autophagy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Deconvoluting the context-dependent role for autophagy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Autophagic cell death: the story of a misnomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The dynamic nature of autophagy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Role of autophagy in cancer: management of metabolic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Autophagy as a therapeutic target in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Role and regulation of autophagy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The multiple roles of autophagy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Review: autophagy in neurodegeneration: firefighter and/or incendiarist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Crosstalk between apoptosis and autophagy within the Beclin 1 interactome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Regulation of autophagy in mammals and its interplay with apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Autophagy modulation for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Loss of Pten, a tumor suppressor, causes the strong inhibition of autophagy without affecting LC3 lipidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Autophagy and ionizing radiation in tumors: the "survive or not survive" dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Endoplasmic reticulum stress mediates radiation-induced autophagy by perk-eIF2alpha in caspase-3/7-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Promotion of autophagy as a mechanism for radiation sensitization of breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Autophagy contributes to resistance of tumor cells to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Cell killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The autophagic paradox in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Biomarkers for epithelial-mesenchymal transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The epithelial-mesenchymal transition generates cells with properties of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Radiation and the microenvironment - tumorigenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Irradiation-induced epithelial-mesenchymal transition (EMT) related to invasive potential in endometrial carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Low doses ionizing radiation enhances the invasiveness of breast cancer cells by inducing epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Stem cell concepts renew cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Prostate cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Methodologies in assaying prostate cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Prostate cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Prospective identification of tumorigenic prostate cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

CD133, a novel marker for human prostatic epithelial stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Radiosensitivity of prostate cancer cells is enhanced by EGFR inhibitor C225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Prostate cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Prostate cancer stem cells: a new target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Stem cell characteristics in prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Exploring the role of cancer stem cells in radioresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Identification of tumor-initiating cells in a p53-null mouse model of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Radiation-induced reprogramming of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Loss of tumor-initiating cell activity in cyclophosphamide-treated breast xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Role of radiation therapy and radiosurgery in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Prostate cancer stem/progenitor cells: identification, characterization, and implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The effects of radiation therapy on bone growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic Bax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Sodium selenite radiosensitizes hormone-refractory prostate cancer xenograft tumors but not intestinal crypt cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFR-expressing androgen-independent prostate tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

RelB-dependent differential radiosensitization effect of STI571 on prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Modulation of radiation response by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

In vitro radiosensitisation by trabectedin in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Monascuspiloin enhances the radiation sensitivity of human prostate cancer cells by stimulating endoplasmic reticulum stress and inducing autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Cyclooxygenase-2 and prostate carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

P53, cell cycle control and apoptosis: implications for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

In vivo imaging, tracking, and targeting of cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

Cancer Stem Cells and Radiotherapy: New Insights Into Tumor Radioresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9493-5

10.1007/S10555-014-9493-5

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference